Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).

doi:10.1016/j.lungcan.2021.08.010

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).

Lung cancer (Amsterdam, Netherlands) - 1 Oct 2021

Nagasaka Misako, Asad Mohammad Fahad B, Al Hallak Mohammed Najeeb, Uddin Md Hafiz, Sukari Ammar, Baca Yasmine, Xiu Joanne, Magee Dan, Mamdani Hirva, Uprety Dipesh, Kim Chul, Xia Bing, Liu Stephen V, Nieva Jorge J, Lopes Gilberto, Bepler Gerold, Borghaei Hossein, Demeure Michael J, Raez Luis E, Ma Patrick C, Puri Sonam, Korn W Michael, Azmi Asfar S

Abstract excerpt

BACKGROUND: Nuclear protein transport is essential in guiding the traffic of important proteins and RNAs between the nucleus and cytoplasm. Export of proteins from the nucleus is mostly regulated by Exportin 1 (XPO1). In cancer, XPO1 is almost universally hyperactive and can promote the export of important tumor suppressors to the cytoplasm. Currently, there are no studies evaluating XPO1 amplifications and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exportin 1 Protein

Share to Karyopherins

Share to Lung Neoplasms

Share to Mutation

Share to Receptors, Cytoplasmic and Nuclear

Source

Open in PubMed Open full text

Identifiers

PMID: 34482103
DOI: 10.1016/j.lungcan.2021.08.010
PMCID: PMC8853639

Provenance

PubMed metadata and Literature Corpus relationships.